Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Erik Volz, Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidelberg, Wes Hinsley, Daniel J. Laydon, Gavin Dabrera, Áine O’Toole, Robert Amato, Manon Ragonnet‐Cronin, Ian Harrison, Ben Jackson, Cristina V. Ariani, Olivia Boyd, Nicholas J. Loman, John T. McCrone, Sónia Gonçalves, David Jorgensen, Richard Myers, Verity Hill, David K. Jackson, Katy A. M. Gaythorpe, Natalie Groves, John Sillitoe, Dominic Kwiatkowski, Seth Flaxman, Oliver Ratmann, Samir Bhatt, Susan Hopkins, Axel Gandy, Andrew Rambaut, Neil M. FergusonNature 2021 · DOI

Introduction

In late 2020, public health authorities in the United Kingdom identified a novel SARS-CoV-2 lineage, B.1.1.7 (later known as the Alpha variant), which was expanding at an unprecedented rate. A critical question for researchers was whether this rapid growth resulted from "founder effects"—stochastic success in high-transmission environments—or a genuine biological increase in transmissibility. Furthermore, early data suggested a higher prevalence of B.1.1.7 in children and teenagers, raising concerns about whether the variant had a biological preference for younger hosts or if social factors, such as schools remaining open during lockdowns, were responsible.

Methodology

To quantify the transmission advantage of B.1.1.7, the study employed a multi-pronged statistical approach:

  1. Phylodynamic Modeling: Researchers analyzed the phylogenetic "family tree" of thousands of viral genomes to estimate effective population sizes and growth rates. By comparing B.1.1.7 to the then-dominant B.1.177 lineage, they isolated the intrinsic growth rate differences.
  2. S-Gene Target Failure (SGTF) Analysis: A specific deletion (69-70) in the B.1.1.7 spike protein causes one of the three probes in the ThermoFisher TaqPath PCR test to fail. This "S-gene dropout" served as a highly specific, real-time biomarker, allowing the team to utilize massive community testing datasets ("pillar 2") that far exceeded the capacity of whole-genome sequencing.
  3. Epidemiological Modeling: A Bayesian framework was used to estimate time-varying reproduction numbers ($R_t$) for both Variant of Concern (VOC) and non-VOC lineages across 42 geographical areas in England.
  4. Age-Stratified Analysis: The team compared the age distribution of SGTF versus non-SGTF cases to determine if the variant possessed a specific transmission advantage in younger populations.
S-gene target failure (SGTF) data and the estimated multiplicative advantage of the B.1.1.7 variant.

Key Results and Insights

The analysis consistently demonstrated a substantial transmission advantage for B.1.1.7. All models converged on a reproduction number ($R$) that was 50% to 100% higher than co-circulating lineages. The variant transitioned from emergence to 50% frequency across England within approximately 2.5 to 3 months.

Regional frequency of B.1.1.7 and phylodynamic comparisons of effective population size and $R_t$ against the B.1.177 lineage.

The SGTF "Biomarker"

The use of SGTF as a proxy was a pivotal methodological innovation. It enabled near-real-time tracking of the variant's spread weeks before genomic sequencing could provide confirmation. As shown in regional case data, S-negative (VOC) cases surged even as S-positive (non-VOC) cases were suppressed by public health interventions.

Demographic Shifts and Policy

While initial data showed a higher proportion of B.1.1.7 cases in individuals under 20, modeling revealed this was not due to biological preference. Instead, it was an artifact of the second UK lockdown, during which schools remained open while other social venues closed. This created a specific transmission niche that the more transmissible variant exploited more effectively than previous strains.

Robustness of the Advantage

The transmission advantage remained significant even when adjusting for potential variations in generation time. Even under the assumption of a shorter generation time, B.1.1.7 still required a significantly higher $R$ to explain the observed epidemiological data.

Conclusion and Implications

The B.1.1.7 lineage represented a major shift in the pandemic's trajectory, with a median additive growth rate difference estimated at 0.69 per week. While subsequent lockdowns eventually reduced absolute case numbers, the relative advantage of B.1.1.7 persisted, making it significantly harder to control than previous strains.

These findings underscore the critical importance of robust global genomic surveillance. The rapid identification of B.1.1.7 was possible only due to the UK's extensive sequencing infrastructure. The authors warn that without similar monitoring worldwide, new variants—including those with potential "immune escape" capabilities—could spread undetected, undermining global vaccination efforts.

Summary updated

BibTeX
@inproceedings{volz2021assessing,
  author = {Erik Volz and Swapnil Mishra and Meera Chand and Jeffrey C. Barrett and Robert Johnson and Lily Geidelberg and Wes Hinsley and Daniel J. Laydon and Gavin Dabrera and Áine O’Toole and Robert Amato and Manon Ragonnet‐Cronin and Ian Harrison and Ben Jackson and Cristina V. Ariani and Olivia Boyd and Nicholas J. Loman and John T. McCrone and Sónia Gonçalves and David Jorgensen and Richard Myers and Verity Hill and David K. Jackson and Katy A. M. Gaythorpe and Natalie Groves and John Sillitoe and Dominic Kwiatkowski and Seth Flaxman and Oliver Ratmann and Samir Bhatt and Susan Hopkins and Axel Gandy and Andrew Rambaut and Neil M. Ferguson},
  title = {{Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England}},
  booktitle = {Nature},
  year = {2021},
  doi = {10.1038/s41586-021-03470-x},
}
Figure